OXANDROLONE Drug Patent Profile
✉ Email this page to a colleague
When do Oxandrolone patents expire, and when can generic versions of Oxandrolone launch?
Oxandrolone is a drug marketed by Par Pharm, Roxane, Sandoz, and Upsher Smith Labs. and is included in five NDAs.
The generic ingredient in OXANDROLONE is oxandrolone. There are ten drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the oxandrolone profile page.
Summary for OXANDROLONE
US Patents: | 0 |
Applicants: | 4 |
NDAs: | 5 |
Finished Product Suppliers / Packagers: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 39 |
Clinical Trials: | 23 |
Patent Applications: | 2,699 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for OXANDROLONE |
DailyMed Link: | OXANDROLONE at DailyMed |
Recent Clinical Trials for OXANDROLONE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University Hospital, Clermont-Ferrand | Phase 2 |
George F. Hatch | Phase 4 |
Sunnybrook Health Sciences Centre | Phase 3 |
Medical Subject Heading (MeSH) Categories for OXANDROLONE
Anatomical Therapeutic Chemical (ATC) Classes for OXANDROLONE
Paragraph IV (Patent) Challenges for OXANDROLONE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
OXANDRIN | Tablets | oxandrolone | 2.5 mg and 10 mg | 013718 | 1 | 2006-06-19 |